Genomic medicine advances for brain tumors.

IF 2.4 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2024-10-01 Epub Date: 2024-05-10 DOI:10.1007/s10147-024-02522-2

Shinichiro Koizumi, Tomoya Oishi, Moriya Iwaizumi, Kazuhiko Kurozumi

{"title":"Genomic medicine advances for brain tumors.","authors":"Shinichiro Koizumi, Tomoya Oishi, Moriya Iwaizumi, Kazuhiko Kurozumi","doi":"10.1007/s10147-024-02522-2","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer genome profiling has revealed important genetic alterations that serve as prognostic indicators and guides for treatment decisions, enabling precision medicine. The shift to molecular diagnosis of brain tumors, as reflected in the 2021 World Health Organization Classification of Tumors of the Central Nervous System, is a crucial role for treatment decision-making. This review discusses the significance and role of cancer genome profiling in precision medicine for malignant brain tumors, particularly gliomas. Furthermore, we explore the progress in cancer genome analysis, focusing on cancer gene panel testing, integration of genomic information in brain tumor classification, and hereditary tumors. Additionally, we discuss the transformative effect of genomic medicine on early detection, risk assessment, and precision medicine strategies. The tumor mutational burden in brain tumors is considered low, but the application of molecular targeted drugs, such as isocitrate dehydrogenase inhibitors, v-raf murine sarcoma viral oncogene homolog B1 inhibitors, fibroblast growth factor receptor inhibitors, neurotrophic tyrosine receptor kinase, mechanistic target of rapamycin inhibitors, and anti-programmed death receptor-1 antibody drugs are promising for glioma treatment. We also discuss the future prospects of molecular targeted drugs.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1407-1416"},"PeriodicalIF":2.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02522-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer genome profiling has revealed important genetic alterations that serve as prognostic indicators and guides for treatment decisions, enabling precision medicine. The shift to molecular diagnosis of brain tumors, as reflected in the 2021 World Health Organization Classification of Tumors of the Central Nervous System, is a crucial role for treatment decision-making. This review discusses the significance and role of cancer genome profiling in precision medicine for malignant brain tumors, particularly gliomas. Furthermore, we explore the progress in cancer genome analysis, focusing on cancer gene panel testing, integration of genomic information in brain tumor classification, and hereditary tumors. Additionally, we discuss the transformative effect of genomic medicine on early detection, risk assessment, and precision medicine strategies. The tumor mutational burden in brain tumors is considered low, but the application of molecular targeted drugs, such as isocitrate dehydrogenase inhibitors, v-raf murine sarcoma viral oncogene homolog B1 inhibitors, fibroblast growth factor receptor inhibitors, neurotrophic tyrosine receptor kinase, mechanistic target of rapamycin inhibitors, and anti-programmed death receptor-1 antibody drugs are promising for glioma treatment. We also discuss the future prospects of molecular targeted drugs.

查看原文本刊更多论文

基因组医学在治疗脑肿瘤方面取得进展。

癌症基因组剖析揭示了重要的基因改变，这些改变可作为预后指标和治疗决策指南，从而实现精准医疗。2021 年世界卫生组织《中枢神经系统肿瘤分类》反映了脑肿瘤向分子诊断的转变，这对治疗决策起着至关重要的作用。本综述讨论了癌症基因组图谱分析在恶性脑肿瘤（尤其是胶质瘤）精准医疗中的意义和作用。此外，我们还探讨了癌症基因组分析的进展，重点关注癌症基因面板测试、脑肿瘤分类中基因组信息的整合以及遗传性肿瘤。此外，我们还讨论了基因组医学对早期检测、风险评估和精准医疗策略的变革性影响。脑肿瘤的肿瘤突变负荷被认为较低，但分子靶向药物，如异柠檬酸脱氢酶抑制剂、v-raf鼠肉瘤病毒癌基因同源物B1抑制剂、成纤维细胞生长因子受体抑制剂、神经营养酪氨酸受体激酶、雷帕霉素机制靶点抑制剂和抗程序性死亡受体-1抗体药物的应用在胶质瘤治疗中大有可为。我们还讨论了分子靶向药物的未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.